Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma
After a 5-year period, more than half of patients who underwent allo-HCT for MCL were still alive.
In a retrospective study of 36 patients, researchers found that allogeneic hematopoietic cell transplantation (allo-HCT) could be a curative treatment in patients with mantle cell lymphoma (MCL).1
After 5 years, more than half (54%) of patients who underwent allo-HCT for MCL were still alive. Median overall survival (OS) was determined to be 86 months. In addition, progression-free survival (PFS) numbers were promising; the median PFS was 54 months, and after 5 years of observation, PFS was 49%.
And for those patients who received allo-HCT as a first-line therapy, overall survival was even better (P= .045), suggesting this intervention may be considered as a first step before other medications are administered.
“Notwithstanding the small sample size and retrospective study design, our findings suggest a role for allo-HCT in selected MCL patients,” the researchers from the Moffitt Cancer Center in Tampa, Florida wrote. “Future prospective studies would be needed to better define the role of allo-HCT in this disease.”
- Sandoval-Sus JD, Faramand R, Chavez J, et al. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2018;2:1-8. doi: 10.1080/10428194.2018.1468894